Electroporation therapy: a new approach for the treatment of head and neck cancer

Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective che...

Full description

Saved in:
Bibliographic Details
Published inIEEE transactions on biomedical engineering Vol. 46; no. 6; pp. 752 - 759
Main Authors Hofmann, G.A., Dev, S.B., Dimmer, S., Nanda, G.S.
Format Journal Article
LanguageEnglish
Published New York, NY IEEE 01.06.1999
Institute of Electrical and Electronics Engineers
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective chemotherapeutic drug, bleomycin. Application of a pulsed electric field results in substantially higher uptake of the drug and enhanced killing of the cancer cells than is possible by conventional methods. The MedPulser(R), a new treatment system for local electroporation therapy (EPT) of head and neck tumors was developed and is described in this paper. EPT with bleomycin has been found to be very effective in killing cancer cells in vitro, in mouse tumor xenografts in vivo, and in tumors in humans. Ten head and neck cancer patients with recurring or unresponsive tumors were enrolled in a Phase I/II clinical trial. Treatment of the entire turner mass in each of eight patients resulted in five complete responses confirmed by biopsy and MRI, and three partial responses (/spl ges/50% shrinkage). Two additional patients who received partial treatment of their tumor mass had local response where treated, but no overall lesion remission. Duration of the complete responses ranges from 2-10 months to date. All patients tolerated the treatment well with no significant local or systemic adverse effects.
AbstractList Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective chemotherapeutic drug, bleomycin. Application of a pulsed electric field results in substantially higher uptake of the drug and enhanced killing of the cancer cells than is possible by conventional methods. The MedPulser, a new treatment system for local electroporation therapy (EPT) of head and neck tumors was developed and is described in this paper. EPT with bleomycin has been found to be very effective in killing cancer cells in vitro, in mouse tumor xenografts in vivo, and in tumors in humans. Ten head and neck cancer patients with recurring or unresponsive tumors were enrolled in a Phase I/II clinical trial. Treatment of the entire tumor mass in each of eight patients resulted in five complete responses confirmed by biopsy and MRI, and three partial responses (> or = 50% shrinkage). Two additional patients who received partial treatment of their tumor mass had local response where treated, but no overall lesion remission. Duration of the complete responses ranges from 2-10 months to date. All patients tolerated the treatment well with no significant local or systemic adverse effects.
Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective chemotherapeutic drug, bleomycin. Application of a pulsed electric field results in substantially higher uptake of the drug and enhanced killing of the cancer cells than is possible by conventional methods. The MedPulser, a new treatment system for local electroporation therapy (EPT) of head and neck tumors was developed and is described in this paper. EPT with bleomycin has been found to be very effective in killing cancer cells in vitro, in mouse tumor xenografts in vivo, and in tumors in humans. Ten head and neck cancer patients with recurring or unresponsive tumors were enrolled in a Phase I/II clinical trial. Treatment of the entire tumor mass in each of eight patients resulted in five complete responses confirmed by biopsy and MRI, and three partial responses ( greater than or equal to 50% shrinkage). Two additional patients who received partial treatment of their tumor mass had local response where treated, but no overall lesion remission. Duration of the complete responses ranges from 2-10 months to date. All patients tolerated the treatment well with no significant local or systemic adverse effects.
Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective chemotherapeutic drug, bleomycin. Application of a pulsed electric field results in substantially higher uptake of the drug and enhanced killing of the cancer cells than is possible by conventional methods. The MedPulser(R), a new treatment system for local electroporation therapy (EPT) of head and neck tumors was developed and is described in this paper. EPT with bleomycin has been found to be very effective in killing cancer cells in vitro, in mouse tumor xenografts in vivo, and in tumors in humans. Ten head and neck cancer patients with recurring or unresponsive tumors were enrolled in a Phase I/II clinical trial. Treatment of the entire turner mass in each of eight patients resulted in five complete responses confirmed by biopsy and MRI, and three partial responses (/spl ges/50% shrinkage). Two additional patients who received partial treatment of their tumor mass had local response where treated, but no overall lesion remission. Duration of the complete responses ranges from 2-10 months to date. All patients tolerated the treatment well with no significant local or systemic adverse effects.
Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane permeability. This effect is being used for the treatment of cancer by intratumoral injection of low dosage of an otherwise marginally effective chemotherapeutic drug, bleomycin. Application of a pulsed electric field results in substantially higher uptake of the drug and enhanced killing of the cancer cells than is possible by conventional methods. The MedPulser(R), a new treatment system for local electroporation therapy (EPT) of head and neck tumors was developed and is described in this paper. EPT with bleomycin has been found to be very effective in killing cancer cells in vitro, in mouse tumor xenografts in vivo, and in tumors in humans. Ten head and neck cancer patients with recurring or unresponsive tumors were enrolled in a Phase I/II clinical trial. Treatment of the entire turner mass in each of eight patients resulted in five complete responses confirmed by biopsy and MRI, and three partial responses ( 50% shrinkage). Two additional patients who received partial treatment of their tumor mass had local response where treated, but no overall lesion remission. Duration of the complete responses ranges from 2-10 months to date. All patients tolerated the treatment well with no significant local or systemic adverse effects
Author Hofmann, G.A.
Dev, S.B.
Nanda, G.S.
Dimmer, S.
Author_xml – sequence: 1
  givenname: G.A.
  surname: Hofmann
  fullname: Hofmann, G.A.
  organization: Genetronics Inc., San Diego, CA, USA
– sequence: 2
  givenname: S.B.
  surname: Dev
  fullname: Dev, S.B.
– sequence: 3
  givenname: S.
  surname: Dimmer
  fullname: Dimmer, S.
– sequence: 4
  givenname: G.S.
  surname: Nanda
  fullname: Nanda, G.S.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1798529$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10356882$$D View this record in MEDLINE/PubMed
BookMark eNqF0U1rFTEUBuAgLfa2unDrQrKQiovRfH-4K6XVQkEEXQ9nkjPc0bmTMZmL9N83l7moK129hPNwEvKek5MpTUjIC87ecc78-5rWKK_FE7LhWrtGaMlPyIYx7hovvDoj56V8r0fllHlKzjiT2jgnNuTLzYhhyWlOGZYhTXTZYob54QMFOuEvCvOcE4Qt7VM-zOiSEZYdTgtNPd0iRApTrDT8oAGmgPkZOe1hLPj8mBfk2-3N1-tPzf3nj3fXV_dNUEIuDTgXI-Oxi6rzvTTaMmZi1KYXKrDII2jLrfJd76KQ1loMlYHphGXchCgvyJt1b33gzz2Wpd0NJeA4woRpX1rPmVFOK1Xl5T-lcFIJbeX_IZdeWiYqfLvCkFMpGft2zsMO8kPLWXuo5JBrJdW-Oi7ddzuMf8m1gwpeHwGUAGOf6zcO5Y-z3mnhK3u5sgERf0-PlzwCytmbnw
CODEN IEBEAX
CitedBy_id crossref_primary_10_1586_14737140_6_5_671
crossref_primary_10_1088_0031_9155_55_4_021
crossref_primary_10_1103_PhysRevE_65_041920
crossref_primary_10_1109_TDEI_2009_5293942
crossref_primary_10_1002_bem_10054
crossref_primary_10_1039_C5SM02029H
crossref_primary_10_1080_0284186X_2016_1207803
crossref_primary_10_1109_TDEI_2009_5211853
crossref_primary_10_1103_PhysRevE_65_021913
crossref_primary_10_1016_j_jbiotec_2004_01_015
crossref_primary_10_1371_journal_pone_0080167
crossref_primary_10_3892_ijo_2013_1774
crossref_primary_10_1186_1756_9966_28_53
crossref_primary_10_1109_TPS_2010_2048045
crossref_primary_10_1038_srep10980
crossref_primary_10_1109_TBME_2003_818466
crossref_primary_10_1109_TBME_2003_818467
crossref_primary_10_1002_pros_21303
crossref_primary_10_1007_s00192_018_3625_3
crossref_primary_10_1155_2017_3624613
crossref_primary_10_3390_cancers13091993
crossref_primary_10_1103_PhysRevE_62_1025
crossref_primary_10_1111_j_1525_1594_2005_29085_x
crossref_primary_10_1016_j_snb_2013_12_107
crossref_primary_10_1038_sj_gt_3301799
crossref_primary_10_1227_01_NEU_0000350864_78326_14
crossref_primary_10_1021_ac900055r
crossref_primary_10_3892_mmr_2013_1421
crossref_primary_10_1016_j_ymthe_2003_08_002
crossref_primary_10_1109_TPS_2002_804177
crossref_primary_10_1109_TBME_2005_845212
crossref_primary_10_1080_15368378_2019_1706553
crossref_primary_10_3390_cancers13061418
crossref_primary_10_1089_10849780152752092
crossref_primary_10_1088_0022_3727_49_36_364003
crossref_primary_10_1080_00016480310001114
crossref_primary_10_3390_ijms17081130
crossref_primary_10_1016_j_colsurfb_2007_02_008
crossref_primary_10_1088_0031_9155_51_12_012
crossref_primary_10_1155_SRCM_2006_85234
crossref_primary_10_1016_j_aorl_2006_08_004
crossref_primary_10_1038_s41598_019_39433_6
crossref_primary_10_1063_1_4901248
crossref_primary_10_1109_27_842905
crossref_primary_10_1109_TDEI_2003_1237327
crossref_primary_10_1177_153303460200100110
crossref_primary_10_1016_j_vaccine_2008_03_058
crossref_primary_10_1109_TPS_2004_832621
crossref_primary_10_1088_1742_6596_1704_1_012004
crossref_primary_10_1016_j_abb_2010_03_008
crossref_primary_10_1109_MEI_2013_6410537
crossref_primary_10_1016_j_snb_2012_02_065
crossref_primary_10_1016_j_sna_2005_05_017
crossref_primary_10_1016_j_bbamem_2014_03_010
crossref_primary_10_1088_0031_9155_59_20_6031
crossref_primary_10_1109_TDEI_2009_5293934
crossref_primary_10_4028_www_scientific_net_AMR_586_421
crossref_primary_10_1016_j_bioelechem_2004_07_004
crossref_primary_10_1209_0295_5075_134_68003
crossref_primary_10_1109_TBME_2014_2367543
crossref_primary_10_1109_TPS_2008_917307
crossref_primary_10_1211_0022357021778268
crossref_primary_10_1109_TPS_2014_2308871
crossref_primary_10_3892_mmr_2012_780
crossref_primary_10_3892_mmr_2014_2953
crossref_primary_10_1109_TBME_2006_889196
crossref_primary_10_1109_TPS_2004_830971
crossref_primary_10_1016_j_ejso_2005_04_007
crossref_primary_10_1007_s11517_009_0508_2
crossref_primary_10_22270_jddt_v11i3_4827
crossref_primary_10_4103_jcrt_jcrt_414_21
crossref_primary_10_1103_PhysRevE_64_011913
crossref_primary_10_1016_S0264_410X_00_00087_6
crossref_primary_10_1007_s10544_008_9220_5
crossref_primary_10_3390_electronics8121477
Cites_doi 10.1016/0005-2736(77)90252-8
10.1002/ijc.2910540413
10.3322/canjclin.46.1.5
10.1016/S0304-4165(96)00147-X
10.1109/MEMB.1986.5006335
10.3109/10717549709052016
10.1006/bbrc.1993.1911
10.1007/978-1-4899-2528-2
10.1016/0302-4598(95)01827-2
10.1016/0006-2952(88)90344-9
10.1016/0304-4165(67)90052-9
10.1016/0005-2736(85)90501-2
10.1177/000348949810700908
10.1128/MCB.14.3.1815
10.1016/0005-2736(94)90045-0
10.1109/MEMB.1996.936254
10.1016/0277-5379(91)90065-L
10.1016/0302-4598(94)80026-X
10.1007/BF01867861
10.1016/0305-7372(94)90013-2
10.1016/0006-291X(86)91084-3
10.1002/(SICI)1097-0142(19960301)77:5<964::AID-CNCR24>3.0.CO;2-0
ContentType Journal Article
Copyright 1999 INIST-CNRS
Copyright_xml – notice: 1999 INIST-CNRS
DBID RIA
RIE
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7U5
8FD
L7M
7QO
FR3
P64
DOI 10.1109/10.764952
DatabaseName IEEE All-Society Periodicals Package (ASPP) 1998–Present
IEEE Electronic Library (IEL)
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Solid State and Superconductivity Abstracts
Technology Research Database
Advanced Technologies Database with Aerospace
Biotechnology Research Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Technology Research Database
Advanced Technologies Database with Aerospace
Solid State and Superconductivity Abstracts
Engineering Research Database
Biotechnology Research Abstracts
Biotechnology and BioEngineering Abstracts
DatabaseTitleList MEDLINE


Engineering Research Database
Technology Research Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: RIE
  name: IEEE Electronic Library (IEL)
  url: https://proxy.k.utb.cz/login?url=https://ieeexplore.ieee.org/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Engineering
EISSN 1558-2531
EndPage 759
ExternalDocumentID 401812
10_1109_10_764952
10356882
1798529
764952
Genre orig-research
Clinical Trial, Phase II
Clinical Trial, Phase I
Clinical Trial
Journal Article
GroupedDBID ---
-~X
.55
.DC
.GJ
0R~
29I
4.4
53G
5GY
5RE
5VS
6IF
6IK
6IL
6IN
85S
97E
AAJGR
AASAJ
AAYJJ
ABQJQ
ABVLG
ACGFO
ACGFS
ACIWK
ACKIV
ACNCT
ACPRK
ADZIZ
AENEX
AETIX
AFFNX
AFRAH
AI.
AIBXA
AKJIK
ALLEH
ALMA_UNASSIGNED_HOLDINGS
ASUFR
ATWAV
BEFXN
BFFAM
BGNUA
BKEBE
BPEOZ
CHZPO
CS3
DU5
EBS
EJD
F5P
HZ~
H~9
IAAWW
IBMZZ
ICLAB
IDIHD
IEGSK
IFIPE
IFJZH
IPLJI
JAVBF
LAI
MS~
O9-
OCL
P2P
RIA
RIE
RIG
RIL
RNS
TAE
TN5
VH1
VJK
X7M
XFK
ZGI
ZXP
08R
AAUGY
ABPTK
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7U5
8FD
L7M
7QO
FR3
P64
ID FETCH-LOGICAL-c423t-a88dd01dbd4b9f3657006dd56f24c0d1da571749bf8d23777ec9f3a6b27016cd3
IEDL.DBID RIE
ISSN 0018-9294
IngestDate Sat Aug 17 02:40:25 EDT 2024
Fri Aug 16 20:53:08 EDT 2024
Fri Aug 16 09:24:54 EDT 2024
Fri Aug 23 01:24:52 EDT 2024
Sat Sep 28 07:34:50 EDT 2024
Sun Oct 29 17:08:26 EDT 2023
Wed Jun 26 19:27:44 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Human
Delivery system
Cell permeability
Rodentia
Electroporation
Review
Malignant tumor
Vertebrata
Mammalia
Bleomycin
Electric field
Treatment
Mouse
Efficiency
Animal
Head and neck
ENT disease
Mechanism of action
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c423t-a88dd01dbd4b9f3657006dd56f24c0d1da571749bf8d23777ec9f3a6b27016cd3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 10356882
PQID 21393702
PQPubID 23462
PageCount 8
ParticipantIDs ieee_primary_764952
proquest_miscellaneous_910648544
proquest_miscellaneous_21393702
proquest_miscellaneous_28342573
pubmed_primary_10356882
crossref_primary_10_1109_10_764952
pascalfrancis_primary_1798529
PublicationCentury 1900
PublicationDate 1999-06-01
PublicationDateYYYYMMDD 1999-06-01
PublicationDate_xml – month: 06
  year: 1999
  text: 1999-06-01
  day: 01
PublicationDecade 1990
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
PublicationTitle IEEE transactions on biomedical engineering
PublicationTitleAbbrev TBME
PublicationTitleAlternate IEEE Trans Biomed Eng
PublicationYear 1999
Publisher IEEE
Institute of Electrical and Electronics Engineers
Publisher_xml – name: IEEE
– name: Institute of Electrical and Electronics Engineers
References ref13
ref12
mir (ref23) 1991; 313
ref14
ref30
ref10
ref2
ref1
ref17
ref19
ref18
okino (ref16) 1987; 78
ref24
kanesada (ref20) 1990; 25
ref26
ref22
chang (ref11) 1992
nelson (ref28) 1994; 14
tounekti (ref27) 1993; 53
ref21
ref8
ref7
ref9
ref4
ref3
ref6
ref5
rudolf (ref25) 1995; 29
nishi (ref15) 1996; 56
nanda (ref29) 1998; 18
References_xml – ident: ref5
  doi: 10.1016/0005-2736(77)90252-8
– ident: ref1
  doi: 10.1002/ijc.2910540413
– ident: ref2
  doi: 10.3322/canjclin.46.1.5
– ident: ref19
  doi: 10.1016/S0304-4165(96)00147-X
– volume: 18
  start-page: 999
  year: 1998
  ident: ref29
  article-title: electroporation therapy of human larynx tumors hep-2 implanted in nude mice
  publication-title: Anticancer Res
  contributor:
    fullname: nanda
– ident: ref8
  doi: 10.1109/MEMB.1986.5006335
– ident: ref22
  doi: 10.3109/10717549709052016
– ident: ref21
  doi: 10.1006/bbrc.1993.1911
– ident: ref10
  doi: 10.1007/978-1-4899-2528-2
– ident: ref14
  doi: 10.1016/0302-4598(95)01827-2
– volume: 78
  start-page: 1319
  year: 1987
  ident: ref16
  article-title: effects of a high-voltage electrical impulse and an anticancer drug on growing tumors
  publication-title: Jpn J Cancer Res
  contributor:
    fullname: okino
– ident: ref17
  doi: 10.1016/0006-2952(88)90344-9
– ident: ref3
  doi: 10.1016/0304-4165(67)90052-9
– volume: 313
  start-page: 613
  year: 1991
  ident: ref23
  article-title: electrochemotherapy, a novel antitumor treatment: first clinical trial
  publication-title: C R Acad Sci Paris III
  contributor:
    fullname: mir
– ident: ref9
  doi: 10.1016/0005-2736(85)90501-2
– ident: ref30
  doi: 10.1177/000348949810700908
– volume: 14
  start-page: 1815
  year: 1994
  ident: ref28
  article-title: dna strand breaks: the dna template alterations that trigger p53-dependent dna damage response pathways
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.14.3.1815
  contributor:
    fullname: nelson
– ident: ref26
  doi: 10.1016/0005-2736(94)90045-0
– ident: ref13
  doi: 10.1109/MEMB.1996.936254
– ident: ref18
  doi: 10.1016/0277-5379(91)90065-L
– ident: ref7
  doi: 10.1016/0302-4598(94)80026-X
– volume: 29
  start-page: 229
  year: 1995
  ident: ref25
  article-title: electrochemotherapy with bleomycin. the first clinical experience in malignant melanoma patients
  publication-title: Radiol Oncol
  contributor:
    fullname: rudolf
– ident: ref4
  doi: 10.1007/BF01867861
– year: 1992
  ident: ref11
  publication-title: Guide to electroporation and electrofusion
  contributor:
    fullname: chang
– volume: 53
  start-page: 5462
  year: 1993
  ident: ref27
  article-title: bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized
  publication-title: Cancer Res
  contributor:
    fullname: tounekti
– ident: ref12
  doi: 10.1016/0305-7372(94)90013-2
– ident: ref6
  doi: 10.1016/0006-291X(86)91084-3
– volume: 56
  start-page: 1050
  year: 1996
  ident: ref15
  article-title: high efficiency in vivo gene transfer using intra arterial plasmid dna injection following in vivo electroporation
  publication-title: Cancer Res
  contributor:
    fullname: nishi
– volume: 25
  start-page: 2640
  year: 1990
  ident: ref20
  article-title: anticancer effect of high voltage pulses combined with concentration dependent anticancer drugs on lewis lung carcinoma, in vivo
  publication-title: J Jpn Soc Cancer Ther
  contributor:
    fullname: kanesada
– ident: ref24
  doi: 10.1002/(SICI)1097-0142(19960301)77:5<964::AID-CNCR24>3.0.CO;2-0
SSID ssj0014846
Score 2.0282836
Snippet Electroporation can deliver exogenous molecules like drugs and genes into cells by pulsed electric fields through a temporary increase in cell membrane...
SourceID proquest
crossref
pubmed
pascalfrancis
ieee
SourceType Aggregation Database
Index Database
Publisher
StartPage 752
SubjectTerms Adult
Aged
Aged, 80 and over
Animals
Antimetabolites, Antineoplastic - administration & dosage
Biological and medical sciences
Biomembranes
Biopsy
Bleomycin - administration & dosage
Cancer
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - pathology
Cell membranes
Cells
Cells (biology)
Chemotherapy
Drug Evaluation, Preclinical
Drugs
Electric field effects
Electroporation - instrumentation
Electroporation - methods
Female
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - pathology
Humans
In vitro
Magnetic Resonance Imaging
Male
Mechanical permeability
Medical sciences
Medical treatment
Mice
Middle Aged
Neck
Neoplasms
Otorhinolaryngology (head neck, general aspects and miscellaneous)
Otorhinolaryngology. Stomatology
Permeability
Remission Induction
Treatment Outcome
Tumors
Title Electroporation therapy: a new approach for the treatment of head and neck cancer
URI https://ieeexplore.ieee.org/document/764952
https://www.ncbi.nlm.nih.gov/pubmed/10356882
https://search.proquest.com/docview/21393702
https://search.proquest.com/docview/28342573
https://search.proquest.com/docview/910648544
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fa9swEBZrH0b70HVZf7hbVjH26lSSZVne2xgJpbBBYYW-BVknvQSc0CQP7V_fk-SkTWlKn2zsE8jS6fTJd_cdIT-V09JaXuSAm3cuBci8kdzm3ElpvfEGbAyQ_acub-TVbXnb8WzHXBjnXAw-c4NwG335MLXL8KvsolII59He7mgmUqrW2mEgdcrJYRzXr6hlRyLEWR3sQmoYCEJZUSqtxcYuFMuqhKBIM8dx8amgxXbEGXee0aeU0j2PhIUh4GQyWC6agX14Qef4zo86JAcdAqW_k8p8Jh9c2yP7z3gJe-Tj387j_oVcD1OdnFmnKjQlbN3_ooYiIqcrTnKK4De8o-vIdTr1FC09UNMCitoJtUHD7o7IzWj4_89l3pVhyC1irUVutAZgHBqQTe2LECvDFECpvJCWAQdT4plQ1o3XIIqqqpxFMaMaUSGetFAck9122rrTEEel0Lg6w8AYNB5ae-eNw-1CV1Zp8Bn5sZqW8SyxbYzjKYXV4ZqGKiO9MIprgdXT_sb8PbWval2KOiPnq_kc4woKbhHTuulyPhY8kAIy8YaELoJpKzJCt0gg6FJSl1Jm5CTpyrP-J5U7e7XbX8leRwSRM_6N7C7ulq6PMGfRfI8K_giSWvnm
link.rule.ids 315,786,790,802,27955,27956,55107
linkProvider IEEE
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwEB2hVuLjUGChkEKphbhmsR3Hcbgh1GqBthJSK_UWOR77UilbdXcP8OsZ29ltiyjilCgZS449nnnOzDwDfNDeKOdEVSI571JJVGWvhCuFV8oFGyy6lCB7qmfn6ttFfTHybKdaGO99Sj7z03ibYvk4d6v4q-xjownOk73dJjfPm1ystQkZKJOrcrigFSxbNdIICd5Gy5CbRopQXtXaGHnHD6WDVWJapF3QyIR8pMX9mDP5nqOnuah7kSgLY8rJ5XS17Kfu1x-Ejv_5Wc9gZ8Sg7HNWmufwwA8TeHKLmXACD0_GmPsL-HGYT8q5GpWF5ZKtn5-YZYTJ2ZqVnBH8je_YJnedzQMjW4_MDkii7pK5qGPXL-H86PDsy6wcD2IoHaGtZWmNQeQCe1R9G6qYLcM1Yq2DVI6jQFvTrlC1fTAoq6ZpvCMxq3vZEKJ0WO3C1jAf_OuYSaXJvHrL0VoyH8YEH6wnh2Eapw2GAt6vp6W7ynwbXdqn8DZe81AVMImjuBFYP92_M3837ZvW1LIt4GA9nx2toRgYsYOfrxadFJEWkMt_SJgqGreqAHaPBMEurUytVAGvsq7c6n9Wub2_dvsAHs3OTo6746-n39_A45EWouTiLWwtr1d-n0DPsn-XlP033Nz9Og
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Electroporation+therapy%3A+a+new+approach+for+the+treatment+of+head+and+neck+cancer&rft.jtitle=IEEE+transactions+on+biomedical+engineering&rft.au=Hofmann%2C+G+A&rft.au=Dev%2C+S+B&rft.au=Dimmer%2C+S&rft.au=Nanda%2C+G+S&rft.date=1999-06-01&rft.issn=0018-9294&rft.volume=46&rft.issue=6&rft.spage=752&rft.epage=759&rft_id=info:doi/10.1109%2F10.764952&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0018-9294&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0018-9294&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0018-9294&client=summon